SLC5A2 and myocardial infarction: First trial to show the effects of SGLT2-inhibitors in acute myocardialinfarction was by Paolisso et al. [34] reporting a significant decreasein initial inflammatory parameters (white-blood-cell count,neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR),neutrophil-to-platelet ratio (NPR), and C-reactive protein) as well as infarctsize (echocardiographic parameters and peak troponin levels) in diabetic patientsalready treated with an SGLT2-inhibitor before myocardial infarction compared toother oral anti-diabetic agents independently of glucose-metabolic control.